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Abstract
Recently, methodology was presented to facilitate the incorporation of interim analyses in stepped-wedge
(SW) cluster randomised trials (CRTs). Here, we extend this previous discussion. We detail how the
stopping boundaries, allocation sequences, and per-cluster per-period sample size of a group sequential
SW-CRT can be optimised. We then describe methods by which point estimates, p-values, and confidence
intervals, which account for the sequential nature of the design, can be calculated. We demonstrate that
optimal sequential designs can reduce the expected required number of measurements under the null
hypothesis, compared to the classical design, by up to 30%, with no cost to the maximal possible required
number of measurements. Furthermore, the adjusted analysis procedure almost universally reduces
the average bias in the point estimate, and consistently provides a confidence interval with coverage
close to the nominal level. In contrast, the coverage of a naive 95% confidence interval is observed to
range between 92 and 98%. Methodology is now readily available for the efficient design and analysis
of group sequential SW-CRTs. In scenarios in which there are substantial ethical or financial reasons
to terminate a SW-CRT as soon as possible, trialists should strongly consider a group sequential approach.
Keywords: Cluster randomized trial; Group sequential; Interim analysis; Stepped-wedge.
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1. Introduction
In a cluster randomised trial (CRT), groups of subjects rather than individuals are randomised to treat-
ment conditions. Today, numerous reasons are recognised for why one may employ a CRT design.
Primarily, CRTs aid in the control of contamination between subjects, where participants from the same
group would likely influence each other if randomised to different treatments. Furthermore, they can
bring increased administrative efficiency, helping to overcome the barriers of contacting and recruiting
large numbers of participants, whilst they additionally allow the study of interventions that could not
be directed toward a single individual. Unfortunately though, there are also several noted disadvantages
to these designs. In particular, since participants from a cluster are likely to be more similar than those
from different clusters, there is a potential for correlation between observations from within each cluster.
This must be accounted for not only in the analysis, but also at the design stage, as standard sample size
calculation formulae are no longer applicable. See, for example, Eldridge and Kerry (2012) [1], Campbell
and Walters (2014) [2], or Hayes and Moulton (2017) [3] for further discussions of these issues.
One sub-category of CRT design that has been the subject of substantial research in recent years
is the stepped-wedge (SW) CRT. The key feature of a SW-CRT is that an experimental intervention is
introduced across the clusters over a number of time periods using one-directional switching only. That
is, once a cluster switches to the experimental intervention in a SW-CRT, it does not revert back to the
control intervention for the remainder of the trial. Today, methodology is well established for sample size
calculation [4, 5, 6, 7], and for data analysis [8, 9, 10], in fixed sample SW-CRTs.
In addition, techniques for applying classical group sequential trial design methodology to SW-CRTs
with interim analyses were recently described [11]. This work followed previous suggestions that early
stopping for efficacy may be important in SW-CRTs given the design is regularly associated with scenarios
in which the experimental intervention is expected to do more good than harm [12]. Whilst a review of
the outcome of completed SW-CRTs led to the proposal that early stopping for futility may be helpful to
guard against the over-enthusiastic use of the design [13]. Ultimately, in this work, it was demonstrated
that the incorporation of interim analyses in to a SW-CRT could bring substantial efficiency gains in
terms of the expected number of required measurements, compared to utilising a classical fixed sample
design.
However, one factor left unexamined was how the design of a group sequential SW-CRT could be
optimised. Optimal fixed sample SW-CRT design has been a topic of much recent interest [14, 15, 16, 17],
with the same also true of the optimisation of stopping boundaries in conventional individually randomised
group sequential trials [18, 19, 20]. For both fixed sample SW-CRTs and group sequential trials, design
optimisation was demonstrated to provide substantial efficiency gains. We may therefore expect that it
would be of great value to establish methodology for optimising the design of group sequential SW-CRTs.
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In addition, methodology for post-trial analysis in group sequential SW-CRTs was not considered by
Grayling et al. (2017a) [11]. It is well known that if a final analysis is performed on data acquired within
a sequential trial, that does not take in to account its sequential nature, then biased point estimates, and
p-values and confidence intervals with incorrect coverage will be routinely acquired [21]. Accordingly, the
lack of available guidance on how to analyse data accrued in a group sequential SW-CRT currently limits
the application of such designs in practice.
In this work, we address these problems. Specifically, we first detail how the stopping boundaries, allo-
cation sequences, and per-cluster per-period sample size of a group sequential SW-CRT can be optimised.
Following this, we describe an approach for acquiring a median unbiased estimator for the treatment ef-
fect, along with methodology for constructing adjusted p-values and confidence intervals. Finally, for two
example trial design scenarios, we explore the efficiency gains optimal designs could bring, and examine
the performance of the proposed procedures for data analysis.
We now proceed by describing the notation utilised in the rest of the paper. The aforementioned
methodology is then presented along with the results of a simulation study. We conclude with a short
discussion.
2. Methods
2.1. Notation, hypotheses and analysis in group sequential SW-CRTs
Define Na = {k ∈ N : k ≤ a} for any a ∈ N, and N+a = Na\{0}. Then, we consider a SW-CRT conducted
in C ∈ N\N1 clusters over T ∈ N\N1 time periods, with m ∈ N\N1 measurements taken per-cluster
per-period, to compare a single experimental intervention to some control. We do not restrict ourselves
to cross-sectional designs (in which the measurements are assumed to be taken on different patients in
each time period) or cohort designs (in which the measurements are assumed to be taken on the same
patients in each time period). However, for simplicity, we focus only on complete block SW-CRTs,
where measurements are accrued on every cluster in every time period. Given this, we denote by X,
dim(X) = C × T , the matrix of binary treatment indicators Xc,t, where Xc,t = 1 if cluster c receives the
intervention in time period t, and Xc,t = 0 otherwise.
Denoting the vector of responses available after time period t ∈ N+T by Y t|m,X , we assume that
Y t|m,X ∼ N(Dt|m,Xβ,Σt|m,X), with ΣT |m,X non-singular. Here the subscript t ∈ N+T indicates we con-
sider the subsections of DT |m,X and ΣT |m,X pertaining to the first t time periods only, where DT |m,X
and ΣT |m,X are designated design and covariance matrices for the vector of responses Y T |m,X . Further-
more, β = (β1, . . . , βp)
> is a specified vector of fixed effects. Note that we have explicitly stated the
distribution conditional on the values of m and X, since these will later be treated as variables to be
determined.
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We assume that we would like to make inference about the final element of β, βp, which we denote
for simplicity by τ . Formally, we test the one-sided hypothesis H0 : τ ≤ 0, against H1 : τ > 0.
A group sequential SW-CRT can then be completely defined given
• A set of integers T = {t1, . . . , t|T |}, with ti ∈ N+T for i ∈ N+|T |, ti > ti−1 for i ∈ N|T |\N1, and
t|T | = T .
• Futility and efficacy boundaries f = (f1, . . . , f|T |)> and e = (e1, . . . , e|T |)>, with (f , e) ∈ B|T | =
{(a, b) ∈ R|T | × R|T | : ∀i ∈ N+|T |−1 ai < bi, a|T | = b|T |}.
With this, |T | analyses are carried out in total, with analysis i ∈ N+|T | conducted after time period
ti ∈ N+T . Explicitly, for each i ∈ N+|T | we compute an estimate for β, βˆi|m,X , using generalised least
squares
βˆi|m,X = (βˆ1,i|m,X , . . . , βˆp,i|m,X)
>,
= (D>ti|m,XΣ
−1
ti|m,XDti|m,X)
−1D>ti|m,XΣ
−1
ti|m,XY ti|m,X . (2.1)
From this, we use the estimate of τ , τˆi|m,X = βˆp,i|m,X , to form the following standardised test statistic
Zi|m,X =
τˆi|m,X
{Var(τˆi|m,X)}1/2
= τˆi|m,X{(D>ti|m,XΣ−1ti|m,XDti|m,X)−1[p,p]}−1/2 = τˆi|m,XI
1/2
i|m,X .
Note that for this to be possible (i.e., for τ to be estimable at every interim analysis), it is important
that at least one cluster receives the intervention in one of the time periods t ∈ N+t1 . This can be verified
using the matrix X by checking
∑
c∈N+C
∑
t∈N+t1
Xc,t > 0.
An algorithm for conducting a group sequential SW-CRT can then be defined as follows
1. Set t = 1.
2. Conduct period t of the trial, allocating treatments according to the values Xc,t for c ∈ N+C , and
accruing m measurements in each cluster.
3. If t /∈ T set t = t+ 1 and return to 2. Otherwise, if t ∈ T , t = ti say, compute Zi|m,X . Then
• If Zi|m,X ≤ fi stop the trial, and do not reject H0.
• If Zi|m,X > ei stop the trial, and reject H0.
• If fi < Zi|m,X ≤ ei, set t = t+ 1 and return to 2.
Here, the trial is guaranteed to terminate, with a decision also made on H0, by the end of time period
T because of the stipulation that f|T | = e|T |.
4
Importantly, (Z1|m,X , . . . , Z|T ||m,X)> is multivariate normal with
E(Zi|m,X) = τI
1/2
i|m,X , i ∈ N+|T |,
Cov(Zi|m,X , Zj|m,X) = (Ii|m,X/Ij|m,X)1/2, i, j ∈ N+|T |, i ≤ j,
and so multivariate normal integration can be used to evaluate the statistical operating characteristics of
the design [21].
To see this clearly, define the random variable Γ ∈ N+|T | as the analysis at which the trial is terminated,
and Ψ ∈ N1 as the random variable with Ψ = 1 if H0 is rejected, and Ψ = 0 otherwise. The possible
outcomes to the trial are then categorised by the pair {Ψ,Γ}, and for any {ψ, γ} ∈ N1 × N+|T |
P(Γ = γ,Ψ = ψ|τ,f , e,m,X) =
∫ u(1,γ,ψ,f ,e)
l(1,γ,ψ,f ,e)
· · ·
∫ u(γ,γ,ψ,f ,e)
l(γ,γ,ψ,f ,e)
φ(y, τI
1/2
γ|m,X ,Λγ|m,X)dyγ . . .dy1, (2.2)
where
• φ{y,µ,Λ} is the probability density function of a multivariate normal distribution with mean µ
and covariance matrix Λ, evaluated at vector y,
• I1/2γ|m,X = (I1/21|m,X , . . . , I1/2γ|m,X)>.
• l and u are functions that provide the lower and upper integration limits for each integral. Explicitly,
for any (f , e) ∈ B|T |
l(i, γ, ψ,f , e) =

fi : i < γ,
ei : i = γ, ψ = 1,
−∞ : i = γ, ψ = 0,
u(i, γ, ψ,f , e) =

ei : i < γ,
∞ : i = γ, ψ = 1,
fi : i = γ, ψ = 0.
• Λγ|m,X is the covariance matrix of the standardized test statistics across the interim analyses
1, . . . , γ
Λγ|m,X =

Cov(Z1|m,X , Z1|m,X) . . . Cov(Z1|m,X , Zγ|m,X)
...
. . .
...
Cov(Zγ|m,X , Z1|m,X) . . . Cov(Zγ|m,X , Zγ|m,X)
 .
With this, the probability that H0 is rejected, and the expected number of required measurements
(ENM), can be computed as
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P (τ | f , e,m,X) =
∑
γ∈N+|T |
P(Γ = γ,Ψ = 1|τ,fγ , eγ ,m,X),
ENM(τ | f , e,m,X) =
∑
γ∈N+|T |
∑
ψ∈N1
mCtγP(Γ = γ,Ψ = ψ|τ,fγ , eγ ,m,X).
2.2. Optimal group sequential designs
Section 2.1 describes a method for conducting a group sequential SW-CRT given choices for several design
parameters. However, at the design stage, we require a method for choosing values for these parameters
to provide desired operating characteristics. One simple approach to this, after designating a value for
X, is the error spending method, as discussed in Grayling et al. (2017a) [11]. Here, we consider instead
how X, f , e, and either C or m, can be optimised.
For this, much depends on whether the choice is to fix C or m. In the former case, the matrix X can
be readily optimised, as will be described shortly. In the latter case, optimisation of X is complex since
its row dimension is variable in the search for the required value of C. In this case, X should be specified
implicitly through rules on what proportion of clusters should switch to the intervention in each time
period, reducing the problem to optimising only f , e, and C. Then, having determined an appropriate
value for C, one can employ the approach for fixed C to optimise X if desired.
Thus, from here, we focus on the problem of simultaneously optimising X, f , e, and m, when C has
been fixed. To this end, define the vector S = (S1, . . . , SC)
> ∈ ST of switching times, where
ST =
s ∈ {N+T+1}C : minc∈N+C sc ≤ t1, ∀t ∈ N+T
∏
c∈N+C
I(sc = t) = 0
 .
That is, Xc,t = I(t ≥ Sc) for (c, t) ∈ N+C × N+T . Here, we have used Sc = T + 1 to indicate that cluster c
does not receive the intervention during the trial, whilst the additional constraints ensure τ is estimable at
every interim analysis, and that at least two distinct sequences of allocations are used across the clusters.
We will use the notation X(S) to indicate the matrix X implied by a particular choice for S.
We then consider an optimal design framework where we wish to identify the solution to a problem
which can be cast in the following form
argmin
{(f ,e),m,S}∈B|S |×(N\N1)×ST
O(f , e,m,S),
subject to
P{0|f , e,m,X(S)} ≤ α, P{δ|f , e,m,X(S)} ≥ 1− β.
6
Here, the constraints are interpreted as controlling the type-I error-rate to some α ∈ (0, 1) when τ = 0,
and to have power of at least 1− β ∈ (0, 1) when τ = δ > 0.
In practice, the objective function O(·) could be specified to be as complex as desired. For example, as
discussed in Grayling et al. (2017c) [22], it could penalise designs which roll-out the intervention beyond
a certain speed, or impose a cost on designs where clusters do not receive the experimental intervention.
Here though, adapting previous relevant works on optimal group sequential trial design [18, 19], we
consider
O(f , e,m,S) = w1ENM{0|f , e,m,X(S)}+ w2ENM{δ|f , e,m,X(S)}+ w3mCT.
With this, the wi ∈ R+ ∪ {0} are weights indicating the relative strengths of the desires to minimise the
ENM under the null, the ENM under the alternative hypothesis, and the maximal required number of
observations. Later, we will use the notation w = (w1, w2, w3).
Unfortunately, the complexity of the constraints on the trial’s operating characteristics means they
cannot easily be incorporated in to a conventional numerical optimisation routine that we may seek to
use to solve the above problem. Therefore, following Wason and Jaki (2012) [18] and Wason et al. (2012)
[19], we translate our problem to be
argmin
{(f ,e),m,S}∈B|S |×(N\N1)×ST
O(f , e,m,S) +MSW
(
I[P{0|f , e,m,X(S)} > α]
[
P{0|f , e,m,X(S)} − α
α
]
+ I[1− P{δ|f , e,m,X(S)} > β]
[
1− P{δ|f , e,m,X(S)} − β
β
])
.
(2.3)
Here MSW is the number of observations required by a corresponding fixed-sample near-balanced SW-
CRT (i.e., a design with as near-equal as possible numbers of clusters switching to the intervention in
each time period). The final factor is thus a penalty for designs that do not meet the desired operating
characteristics, to assist in converging towards a solution meeting these requirements.
The final challenge therefore is to identify the solution of the problem (2.3). For this, a numerical
optimisation routine capable of handling the fact that m and the Sc are discrete, but the components
of f and e are continuous, is required. This algorithm must also be capable of handling the many local
optima the search space will likely contain. One such routine, available in R, is the CEoptim function
from the package of the same name [23]. We utilise this for all examples given here, and in the Appendix
we elaborate on our choices for the algorithms initialisation.
Our full procedure for optimising the design of a group sequential SW-CRT has then been prescribed.
In Section 3.1 we present numerous such optimal designs.
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2.3. Post trial analysis: Point estimates, p-values, and confidence intervals
In this section, we turn our attention to the final analysis of data accrued in a completed group sequential
SW-CRT. For notational simplicity, we therefore suppose that the trial was conducted using design
D = {T ,f , e,m,X} (i.e., these factors are all fixed and known in what follows). Additionally, we
assume that the trial terminated with {Γ, ZΓ|m,X} = {γ, zγ} ∈ ΞD = {{i, zi} ∈ T × R : zi /∈ (fi, ei]}.
With this, a simple method for specifying a point estimate for the treatment effect τ , is to use the
maximum likelihood estimate (MLE) τˆN = τˆγ|m,X = βˆp,γ|m,X , as defined by Equation (2.1). Additionally,
one could designate a p-value as pN = 1 − Φ(zγ), where Φ(z) is the cumulative density function of the
standard normal distribution. Finally, a one-sided confidence interval for τ , could be taken as CN =
(τˆLCI,N,∞) for τˆLCI,N = τˆN − Φ−1(1− α)I−1/2γ|m,X .
The problem with these methods however is that they do not take into account the sequential nature
of the design. As was noted in Section 1, such naive analysis procedures, as the subscript N is meant
to indicate, will routinely result in biased point estimates, and p-values and confidence intervals with
incorrect coverage. For example, Tsiatis et al. (1984) [24] demonstrated that the coverage of a naive 90%
confidence interval at the end of a four-stage group sequential trial could be as low as 0.846.
Accordingly, methodology for performing an adjusted analysis is required. Unfortunately, there is
no method that is optimal for analysis following a sequential trial in all situations. Whitehead (1986)
[25] proposed one of the first methods for analysing data accrued in a group sequential trial, suggesting
that the point estimate be taken as the solution to a simple equation involving the computation of the
expected bias in the estimated treatment effect. This estimator was demonstrated to typically have
extremely small bias. However, its evaluation is complex and it provides no easy means of nominating an
associated confidence interval with the desired coverage. Emerson and Fleming (1990) [26] suggested use
of a uniform minimum variance unbiased estimator, formed through Rao-Blackwellisation of the unbiased
estimate of τ from the first stage data. Unfortunately, this estimator was found to have large variance.
Consequently, we instead present an approach that is both easy to apply, and generally has good
performance. We use the so-called stage-wise ordering in a group sequential design to designate p-values
and confidence intervals with exact coverage probabilities, and to specify a median unbiased point estimate
for τ . These computations will require evaluation only of integrals of the form in Equation (2.2).
The stage-wise ordering was first proposed by Armitage (1957) [27], and has subsequently been utilised
in many papers on individually randomised group sequential trials (see, for example, Siegmund (1978)
[28] and Tsiatis et al. (1984) [24]). For any {i, zi}, {j, zj} ∈ ΞD , the stage-wise ordering considers {i, zi}
to be more extreme than {j, zj} if i < j or if i = j and zi ≥ zj . This ordering can then be used to
derive our adjusted p-values and confidence intervals, as well as the median unbiased point estimate.
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Specifically, define
E(τ | i, zi,f , e,m,X) =
∑
j∈N+i−1
P(Γ = j,Ψ = 1|τ,f j , ej ,m,X),
+ P{Γ = i,Ψ = 1|τ,f i, (e>i−1, zi)>,m,X},
which is the probability, for the given stage-wise ordering, of seeing a result more extreme than (i, zi) for
a particular value of τ .
Using this, an overall p-value for H0 can be taken as pSO = E(0 | γ, zγ ,f , e,m,X). Similarly, the
associated adjusted confidence interval is CSO = (τˆLCI,SO,∞), where τˆLCI,SO is the solution of α =
E(τˆLCI,SO | γ, zγ ,f , e,m,X). Finally, a median unbiased estimate can be designated as the solution τˆSO
to 0.5 = E(τˆSO | γ, zγ ,f , e,m,X).
Both τˆLCI,SO and τˆSO can be determined using a simple one-dimensional root finding algorithm, and
thus we have established a potential means of performing an improved final analysis on data in group
sequential SW-CRTs.
To examine the statistical performance of these analysis procedures, we simulate R = 105 trials for
several optimised group sequential designs D and values for τ . The details of the data degeneration
procedure in the simulation study are described in the Appendix. From this, for each considered design
we compute, for r ∈ N+R, Cx,r(τ |D) and τˆx,r(τ |D) for x ∈ {N,SO}. Here, τˆx,r(τ |D) is, in a trial using
design D , the point estimate at the final analysis for simulation r using estimator x, when the true
treatment effect is τ , with an analogous definition holding for Cx,r(τ).
The performance of the two point estimation procedures is then assessed using the average bias and
average root mean square error (RMSE), computed as
b(τ | x,D) = R−1
∑
r∈N+R
{τˆx,r(τ |D)− τ}, RMSE(τ | x,D) =
√
R−1
∑
r∈N+R
{τˆx,r(τ |D)− τ}2.
Similarly, the confidence intervals are compared using their respective coverages, given by
COV (θ | x,D) = R−1
∑
r∈N+R
I{τ ∈ Cx,r(τ |D)}.
2.4. Examples
We follow Grayling et al. (2017a) [11] and consider two example trial design scenarios (TDSs). In both,
we assume a cross-sectional design, with analysis conducted utilising the following linear mixed model,
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as proposed by Hussey and Hughes (2007) [4]
yijk = µ+ pij + τXij + ci + ijk,
for i ∈ N+C , j ∈ N+T , and k ∈ N+m. Here
• yijk is the response of the kth individual in the ith cluster and jth time period.
• µ is an intercept term.
• pij is a fixed effect for the jth period (with pi1 = 0 for identifiability).
• ci ∼ N(0, σ2c ) is a random effect for the ith cluster.
• eijk ∼ N(0, σ2e) is the residual error.
Now, for TDS1, we consider the SW-CRT reported by Bashour et al. (2013) [29], on the effect of
training doctors in communication skills on women’s satisfaction with doctor-woman relationship during
labour and delivery. In this trial, a balanced four cluster five period design was used, and the final
analysis estimated that σ2c = 0.02 and σ
2
e = 0.51. Based on this, a sample size of 70 patients per-cluster
per-period would have been required for the trial’s desired operating characteristics (α = 0.05, β = 0.1,
and δ = 0.2), implying a total sample requirement of 1400 subjects. Thus, in TDS1 we fix C = 4, T = 5,
σ2c = 0.02, σ
2
e = 0.51, α = 0.05, β = 0.1, δ = 0.2, and MSW = 1400.
For TDS2, we base our design parameters on the average characteristics of completed SW-CRTs as
reported in Grayling et al. (2017a) [11]. We set C = 20 and T = 9, to correspond to the median values
used in-practice. Next, we suppose α = 0.05, β = 0.2, and choose σ2e = 1, σ
2
c = 1/9, to provide a more
moderate value for the intra-cluster correlation compared to TDS1. In a near-balanced design (i.e., one
where three clusters switch to the intervention in the second through fifth periods, and two clusters in
each of the remaining time periods), a design with m = 7 and δ = 0.24 provides the desired power and
type-I error-rate. This will therefore be our designated value of δ, and MSW = 1260.
Note that in these scenarios, DT |m,X and ΣT |m,X can be specified easily for any m and X. Moreover,
recalling that C and T are designated for any X by the relationship dim(X) = C×T , we can then easily
determine It|m,X using the result of Hussey and Hughes (2007) [4]
It|m,X =
(σ2 + tσ2c )(CU −W ) + σ2c (U2 − CV )
Cσ2(σ2 + tσ2c )
,
for σ2 = σ2e/m, and where
U =
∑
c∈N+C
∑
j∈N+t
Xc,j , V =
∑
c∈N+C
∑
j∈N+t
Xc,j
2 , W = ∑
j∈N+t
∑
c∈N+C
Xc,j
2 .
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Code to replicate our determination of optimal designs, and to explore the performance of the con-
sidered analysis procedures, is available from https://github.com/mjg211/article code.
3. Results
3.1. Optimal designs
For the TDSs described in Section 2.4, a numerical search was performed to identify the optimal values
of e, f , m, and X for w ∈ {(1/3, 1/3, 1/3), (1/2, 1/2, 0), (0, 1/2, 1/2)}, with T = {3, 5} in TDS1 and
T = {3, 6, 9} in TDS2. The determined optimal designs, and a summary of their statistical operating
characteristics, are presented in Table 1. Their type-I error-rates and power are omitted as each was
verified to be the desired level.
TDS w m S> f> e> ENM(0) ENM(δ)
TDS1
(1/3, 1/3, 1/3) 69 (1,2,3,5) (0.41,1.66) (2.27,1.66) 1010.0 1073.7
(1/2, 0, 1/2) 70 (1,2,3,5) (0.68,1.60) (2.95,1.60) 978.6 1219.0
(0, 1/2, 1/2) 69 (1,2,3,5) (-5.05,1.71) (2.12,1.71) 1370.7 1055.8
TDS2
(1/3, 1/3, 1/3) 7
(1, 1, 1, 2, 2, 2, 3, 3, 4, 4,
(-0.07,0.67,1.65) (2.64,2.14,1.65) 725.5 923.2
5, 5, 6, 6, 6, 8, 8, 8, 9, 10)
(1/2, 0, 1/2) 7
(1, 1, 1, 1, 2, 2, 2, 3, 3, 3,
(0.04,0.77,1.58) (14.41,12.93,1.58) 705.7 1184.1
4, 5, 5, 6, 6, 7, 7, 8, 8, 9)
(0, 1/2, 1/2) 7
(1, 1, 1, 1, 2, 2, 2, 3, 3, 3,
(-5.55,-4.33,1.79) (2.26,2.05,1.79) 1243.9 923.7
4, 5, 5, 6, 6, 7, 8, 8, 9, 9)
Table 1: Example optimal designs are shown for the two example trial design scenarios (TDSs) given in
Section 2.4. For brevity, here ENM(τ) = ENM{τ |f , e,m,X(S)}. The boundary and expected number
of measurement (ENM) values are given to two and one decimal place respectively.
In all instances the ENM under the null and alternative hypotheses is substantially reduced compared
to the corresponding fixed sample design. Specifically, in TDS1 it is by as much as 30.1% under the null
hypothesis, with w = (1/2, 0, 1/2), and 24.6% under the alternative hypothesis, with w = (0, 1/2, 1/2).
For TDS1, we can observe that the ability to alter X has allowed the three designs to incorporate
interim analyses without the need to increase the value of m. We also see that the optimal choice for X
is the same for each value of w. However, as would be expected, the ENMs required under the null and
alternative hypotheses is strongly dependent on the choice of w. For example, with w = (1/2, 0, 1/2) the
value of ENM(0) is lower, and the value of ENM(δ) higher, than with w = (1/3, 1/3, 1/3). A similar
statement holds for the design with w = (0, 1/2, 1/2). This is a consequence of the identified optimal
boundaries. For example, the design with w = (0, 1/2, 1/2) has f1 = −5.05, almost ensuring the trial
will not stop early for futility, as no concern is given to stopping early under the null hypothesis.
Similar statements hold for TDS2. However, here, the optimal S varies for each considered w.
Additionally, in this case, setting w = (0, 1/2, 1/2) results in a design with approximately the same
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required sample size under the alternative hypothesis as for w = (1/3, 1/3, 1/3). It appears that this
value is approximately the lowest that can be attained for this TDS. However, these two designs have
noticably different features outside of ENM(δ). As for TDS1, w = (0, 1/2, 1/2) results in a design with
lower values for the early efficacy stopping boundaries, and almost removes the possibility to stop early
for futility. This is a feature that should be anticipated in general.
3.2. Post-trial analysis
For the optimal designs given in Table 1, a simulation study was conducted as described in Section 2.3
to evaluate the performance of the naive and adjusted analysis procedures. In each case, we set µ =
pi1 = · · · = piT = 0 for simplicity. Figure 1 displays the average bias and RMSE of the point estimates,
as well as the coverage of the confidence intervals, in TDS1, when τ ∈ [−0.3, 0.5]. Figure 2 displays the
equivalent findings for TDS2.
For both TDSs, the naive point estimator has, for certain values of τ , large bias. The particular shape
of the bias curve is largely dictated by the stopping boundaries. For example, in TDS2, the design with
w = (1/2, 0, 1/2) (Design 2) will rarely stop early for efficacy given the optimal values of e1 and e2 in this
instance. Accordingly, there is only ever a negative average bias in the point estimate. Similar statements
hold for w = (0, 1/2, 1/2) (Design 3) in TDS2 also. These patterns are less clear in TDS1 however, as the
optimal boundaries had a smaller magnitude on average. Importantly, the adjusted procedures almost
universally reduce the average bias in the point estimate. However, this does come at a small cost to the
RMSE in some instances.
For the confidence intervals, the coverage of the naive procedures varies widely, reaching nearly 98%
for the design with w = (1/2, 0, 1/2) (Design 2), and below 92% for w = (0, 1/2, 1/2) (Design 3), in TDS2
for certain values of τ . In contrast, the adjusted method provides approximately the desired coverage
across all designs, and all values of τ .
4. Discussion
In this paper, we have described methodology which allows the design of a group sequential SW-CRT
to be optimised. In addition, we have detailed an approach through which post trial analysis can be
conducted to account for the inclusion of interim analyses, reducing the bias in point estimates and
improving the coverage over a naive final analysis. Ultimately, it is clear that our search procedure is
able to identify highly efficient group sequential SW-CRT designs. In addition, the adjusted analysis
procedures were able to substantially improve performance relative to the naive methods, reducing bias
and providing coverage closer to the desired level.
One important point to discuss further is the influence of the choice of w. It is clear from Table 1 that
12
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Figure 1: The estimated average bias and RMSE of the considered point estimates, and estimated
coverage provided by the confidence intervals is shown from Trial Design Scenario 1. Design 1 is that
shown in Table 1 for w = (1/3, 1/3, 1/3), Design 2 that for w = (1/2, 0, 1/2), and Design 3 that for
w = (0, 1/2, 1/2). The naive (N) procedures are shown via the solid lines, and those based on the
stagewise ordering (SO) via the dashed line.
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Figure 2: The estimated average bias and RMSE of the considered point estimates, and estimated
coverage provided by the confidence intervals is shown from Trial Design Scenario 2. Design 1 is that
shown in Table 1 for w = (1/3, 1/3, 1/3), Design 2 that for w = (1/2, 0, 1/2), and Design 3 that for
w = (0, 1/2, 1/2). The naive (N) procedures are shown via the solid lines, and those based on the
stagewise ordering (SO) via the dashed line.
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by altering w it is possible to improve performance, in terms of the ENM, under the null or alternative
hypothesis. However, setting any of the wi equal to zero can lead to undesirable results. For example,
ENM(0) for the design with w = (0, 1/2, 1/2) in TDS1 was extremely large compared to the two other
presented designs. This fact has been noted previously in other trial design settings [30]. It is advisable
generally to set wi 6= 0 for i = 1, 2, 3, and arguably the balanced optimal design with w = (1/3, 1/3, 1/3)
should usually be preferred.
Another important result arose as a consequence of permitting the optimisation of X. It is extremely
common in group sequential trials that the maximal required sample size is larger than that of a corre-
sponding fixed trial design. Here though, compared to a balanced fixed-sample SW-CRT, the optimal
designs did not require any additional patients. This means that the optimal sequential designs can
perform no worse than a balanced fixed-sample design in terms of the required number of measurements.
Thus, as was discussed at length in Girling and Hemming (2016) [15] and Grayling et al. (2017c) [22], if
it is possible to utilise an optimised (typically non-balanced) X, this should be done, as large efficiency
gains will likely be possible.
In summary, we have presented methodology to allow efficient group sequential SW-CRTs to be deter-
mined, and also to permit a corresponding post trial analysis to be performed with desirable performance.
In practice, these methods are also easy to implement. We have provided code to replicate our presented
results, but all that is required is the ability to evaluate multivariate normal integrals. One drawback
that should be noted though is that there is no guarantee that the search procedure will converge to the
truly optimal design; more likely it will only be approximately optimal. Ideally, one should therefore
check convergence by performing multiple searches from different randomised starting values.
An interesting avenue for future work would be to examine whether there is any pattern to the optimal
value of X depending on the choices for w and T . In particular, whether these are similar to the findings
obtained for fixed sample SW-CRTs would be of great interest, as this may then permit the run time of
the search procedure for finding optimal sequential designs to be improved by utilising these results as
the starting point.
Finally, it is important to recognise that the practical limitations of incorporating interim analyses in
to a SW-CRT as discussed in Grayling et al. (2017a) [11] still stand. However, these notwithstanding,
future trials should in our opinion consider incorporating at least one interim analysis in to a SW-CRT
whenever possible. This will provide the majority of the efficiency gains from a sequential approach,
whilst minimising the alterations required to the trials conduct.
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A. Appendix
A.1. CEoptim initialisation
In Section 3.1 we discussed our approach for simultaneously optimising X, f , e, and m, when C had
been fixed. Ultimately, we were left to find the solution to the problem defined by Equation (2.3), and
proposed to use the function CEoptim in R for this. Here, we describe our initialisation of this function.
The problem (2.3) imposes the following constraints on {(f , e),m,S}
1. m ∈ N\N1.
2. Sc ∈ N+T+1 for c ∈ N+C .
3. minc∈N+C Sc ≤ t1.
4.
∏
c∈N+C I(Sc = t) = 0 for t ∈ N
+
T .
5. {f , e} ∈ R|T | × R|T |
6. fi < ei for i ∈ N|T |−1.
7. f|T | = e|T |.
Here, constraints 2-4 are to ensure that S ∈ ST , whilst constraints 5-7 guarantee {f , e} ∈ B|T |.
In CEoptim, discrete parameters can be incorporated for by direct specification of a set of allowed
values. Consequently, constraint 2 was included easily, whilst constraint 1 could be practically achieved by
setting m ∈ Nmmax for some suitably large mmax ∈ N\N1. For our example, we set mmax = 10NSW /CT .
Moreover, to ensure constraint 3 was adhered to, we designated without loss of generality that S1 ∈ N+t1 .
To include constraints 5-7, rather than optimising the parameters f and e, we transformed our problem
to require optimisation of f and r = (e1−f1, . . . , e|T |−1−f|T |−1)>. For, {f , r} completely defines a pair
{f , e} conforming to constraints 5-7 if {f , r} ∈ R|T |×{R+}|T −1|, which are linear constraints supported
by CEoptim.
Unfortunately, constraint 4 could not be incorporated using the input parameters that can be passed
to CEoptim. Nor would a convenient transformation of the problem work as above. Our solution therefore
was, for each parameter set {(f , e),m,S} considered in the search, to manually check whether constraint
4 was met. In the event that it was not, O(f , e,m,S) was assigned to be infinite to ensure the design
was rejected.
Note that in treating m as discrete, we deviated from the approach taken in, for example, Wason
(2015) [31]. This was advantageous in that then only a single optimisation run was required to determine
the optimal implementable design.
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Now whilst the above ensured our determined optimal solution would confirm to all requirements
placed on the design parameters, this is only one aspect of utilising CEoptim. Like many other global
continuous optimisation routines, CEoptim allows the specification of several control parameters of the
underlying algorithm’s execution. These include an initial probability mass function for the discrete
parameters, initial mean values and standard deviations for the continuous parameters, a sample size
for each iteration of the algorithm, and a rarity parameter used in ‘elite’ design selection. For more
information on these, we refer the reader to Benham et al. (2017) [23].
Fortunately, the cross entropy method is relatively robust to its initialisation. Therefore we placed
uniform distributions on the discrete parameters, as well as means of 0 and a (large) standard deviation
of 10 on the continuous parameters. We also heeded the advice of Benham et al. (2017) [23], and set
the rarity parameter ρCE = 0.01. Moreover, it was advised that the sample size for each iteration, NCE ,
be chosen so that NCEρCE is of the order 10 times the dimension of the optimisation problem. The
dimension of our problem is C + 2|T |. Accordingly, we set NCE = 10000(C + 2|T |). Of course, these
choices may be sub-optimal, and attempts could be made to improve upon them. Practically however,
the search procedure is robust and efficient enough that this is not necessary. Indeed, as was seen, for
the considered examples our utilised approach led to efficient design determination.
Finally, it is important to note the redundancy which exists in the specification of the vector S, which
we were forced to accept within our search procedure. This is a result of the fact that, for example,
O{f , e,m, (1, 2, 3, 4)>} = O{f , e,m, (2, 1, 3, 4)>}. We may anticipate that we could remove the presence
of this redundancy by enforcing Sc ≥ Sc−1 for c ∈ NC\N2, using either a manual check on candidate
design proposal (as for constraint 4 above), or an approach similar to that taken for constraints 5-7 with
the introduction of r.
Unfortunately, the latter approach fails because there is then no effective means of ensuring that
Sc ∈ N+T+1 for c ∈ N+C . Moreover, a manual check is only a viable solution when C is small. To see this,
consider the probability of randomly choosing an S with Sc ≥ Sc−1 for c ∈ NC\N2, which is given by
t1∑
s1=1
T+1∑
sc=s1
· · ·
T+1∑
sc=sc−1
C∏
c=1
P(Sc = sc). (A.1)
Suppose for example that S1 ∼ U{1, t1} and Sc ∼ U{1, T + 1} for c ∈ NC\N2, as is the case at the
beginning of our search given the specifications above. Then, Table A.1 presents the probability (A.1)
when t1 = T/2 for several C ∈ N\N1 and T ∈ N\N1. Clearly, without utilising an intractably large value
for NCE , this approach is in general not feasible as the chance of selecting a design that would pass our
manual check is unacceptably small.
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T = 2 T = 4 T = 6 T = 8 T = 10
C = 2 1.0× 100 0.9× 10−1 8.6× 10−1 8.3× 10−1 8.2× 10−1
C = 4 3.7× 10−1 2.2× 10−1 1.7× 10−1 1.5× 10−1 1.3× 10−1
C = 6 8.6× 10−2 2.9× 10−2 1.7× 10−2 1.2× 10−2 9.4× 10−3
C = 8 1.6× 10−2 2.9× 10−3 1.1× 10−3 6.5× 10−4 4.4× 10−4
C = 10 2.8× 10−3 2.4× 10−4 6.4× 10−5 2.8× 10−5 1.5× 10−5
C = 15 2.5× 10−5 3.1× 10−7 2.6× 10−8 5.3× 10−9 1.7× 10−9
C = 20 1.8× 10−7 2.7× 10−10 6.7× 10−12 5.7× 10−13 9.8× 10−14
Table A.1: The probability of randomly generating a vector S = (S1, . . . , SC)
> with Sc ≥ Sc−1 for
c ∈ NC\N2, when S1 ∼ U{1, T/2} and Sc ∼ U{1, T + 1} for c ∈ NC\N2, is shown for (C, T ) ∈
{2, 4, 6, 8, 10, 15, 20} × {2, 4, 6, 8, 10}.
A.2. Simulation study
Here, we describe how we generated trial data during the simulation study. The assumed correlation
structure of the accrued responses in a SW-CRT means more complex methods are required for this,
compared to the simulation of individually randomised trials for example.
First, recall that Y t|m,X ∼ N(Dt|m,Xβ,Σt|m,X). For simplicity, from here drop explicit reference to
m and X and write Y t ∼ N(Dtβ,Σt). Then, for any set P = {t1, . . . , t|P|} with ti ∈ N+T for i ∈ N+|P|,
define Y P = (Y
>
t1 , . . . ,Y
>
t|P|)
>. Here for any j ∈ N+T , Y j , dim(Y j) = mC×1, is the vector of responses
from time period j ∈ N+T .
Using this, write
Y N+t−1
Y t
 ∼ N

DN+t−1
Dt
β,
ΣN+t−1,N+t−1 ΣN+t−1,t
Σt,N+t−1
Σt,t

 ,
with for any sets P and Q, DP and ΣP,Q defined similarly as for Y P above.
Finally, we generate the Y t as follows. Suppose that Y N+t−1
has been generated for some t ∈ NT \N1,
Y N+t−1
= yN+t−1
say. Then
(Y t | Y N+t−1 = yN+t−1) ∼ N{Dtβ+ Σt,N+t−1Σ
−1
N+t−1,N
+
t−1
(yN+t−1
−DN+t−1β),Σt,t−Σt,N+t−1Σ
−1
N+t−1,N
+
t−1
ΣN+t−1,1
},
meaning Y t can be generated using standard methods for generating random vectors following specified
multivariate normal distributions.
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